Form 483 re­veals qual­i­ty con­trol ques­tions and lack of train­ing at Sun Phar­ma’s plant in In­dia

The FDA has lift­ed the cov­ers on an­oth­er drug man­u­fac­tur­ing fa­cil­i­ty in In­dia re­cent­ly, re­veal­ing sev­er­al con­cerns around san­i­ta­tion and im­prop­er con­trols, among oth­er in­frac­tions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER